# KALA catalysts: KALA BIO, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/kala/catalysts

> KALA BIO, Inc. (KALA) has no upcoming catalysts in this calendar. The latest recorded is the KALA BIO, Inc. earnings report, November 9, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for KALA?

KALA BIO, Inc. (KALA) has no upcoming catalysts in this calendar. The latest recorded is the KALA BIO, Inc. earnings report, November 9, 2026. Press release filed with the SEC (EX-99): "York, November 9, 2026 - KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026." [Calendar and source filings](https://sec-api.dev/companies/kala/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001829126-26-012118, https://www.sec.gov/Archives/edgar/data/1479419/000182912626012118/kalabio_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/kala/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | KALA BIO, Inc. |
| Ticker | KALA (Nasdaq) |
| SEC CIK | 1479419 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/kala |

## Cash runway

Cash $7.2M as of 2026-06-30; quarterly burn $1.5M; about 14.1 months of runway at that rate (XBRL company facts, accession 0001104659-26-098783).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 7, 2019 | [Eysuvis (loteprednol etabonate) complete response letter (CRL)](https://sec-api.dev/pdufa/loteprednol-etabonate) | KALA |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210933_2021_Orig1s000OtherActionLtrs.pdf%22)) |
| Feb 2023 | [KPI-012 trial start](https://sec-api.dev/pdufa/kpi-012) | KALA |  | completed | "In February 2023, we dosed the first patient in the CHASE trial of KPI-012 in patients with PCED in the United States." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1479419/000110465926043782/kala-20251231x10k.htm)) |
| November 12, 2024 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112xex99d1.htm)) |
| March 31, 2025 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331xex99d1.htm)) |
| Q2 2025 | [KPI-012 topline data readout](https://sec-api.dev/pdufa/kpi-012) | KALA | PCED and plans to report topline data | scheduled | ""With over 80% of enrollment now complete in the CHASE trial, we remain on track to report topline data in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000110465924132308/tm2432193d1_ex99-1.htm)) |
| Q2 2025 | [KALA BIO, Inc. topline data readout](https://sec-api.dev/companies/kala/catalysts) | KALA |  | scheduled | "We are targeting reporting topline safety and efficacy data from the CHASE trial in the second quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1479419/000155837024015302/kala-20240930x10q.htm)) |
| May 14, 2025 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514xex99d1.htm)) |
| July 15, 2025 | [KALA BIO, Inc. PDUFA date](https://sec-api.dev/companies/kala/catalysts) | KALA |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1479419/000155837025010853/kala-20250630x10q.htm)) |
| August 8, 2025 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808xex99d1.htm)) |
| Sep 2025 | [KALA BIO, Inc. topline data readout](https://sec-api.dev/companies/kala/catalysts) | KALA |  | scheduled | "We expect to report topline safety and efficacy data from the CHASE trial at the end of September 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1479419/000155837025010853/kala-20250630x10q.htm)) |
| Sep 2025 | [KPI-012 topline data readout](https://sec-api.dev/pdufa/kpi-012) | KALA | PCED and plans to report topline data | scheduled | "-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808xex99d1.htm)) |
| November 9, 2026 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "York, November 9, 2026 - KALA BIO, Inc. (Nasdaq: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000182912626012118/kalabio_ex99-1.htm)) |

## Drugs

- [KPI-012](https://sec-api.dev/pdufa/kpi-012): pced and plans to report topline data

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/kala/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KALA catalysts: KALA BIO, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/kala/catalysts

```bibtex
@misc{secapidev_companies_kala_catalysts_20261116,
  title        = {KALA catalysts: KALA BIO, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/kala/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_kala_catalysts_20261116","title":"KALA catalysts: KALA BIO, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/kala/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
